This severe type of fatty liver disease is associated with obesity and type 2 diabetes and can progress to cirrhosis, liver failure, or liver cancer.
Clinical trials showed no major side effects. REPRESENTATION PIC
Scientists at the University of California have developed a drug that could provide a new treatment for metabolic dysfunction-associated steatohepatitis (MASH).
This severe type of fatty liver disease is associated with obesity and type 2 diabetes and can progress to cirrhosis, liver failure, or liver cancer.
The drug, ION224, blocks a liver enzyme called DGAT2, essential for the liver’s process of producing and storing fat. Inhibiting it reduces fat accumulation and inflammation.
A clinical trial was carried out at multiple centres across the US, enrolling 160 adults diagnosed with MASH and showing early to moderate fibrosis.
Over a year, participants were given monthly injections of either varying doses of ION224 or a placebo. Results revealed that at the highest dose, 60 per cent of patients experienced significant improvements.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
